Amneal Reports P-III Study Results of IPX203 for the Treatment of Parkinson’s Disease

Share this

Amneal Reports P-III Study Results of IPX203 for the Treatment of Parkinson’s Disease


  • The company published the 20wk. P-III (RISE-PD) clinical study results in the JAMA Neurology evaluating IPX203 vs optimized immediate-release carbidopa/levodopa (IR CD/LD) in a ratio (1:1) in patients with Parkinson’s disease who have motor fluctuations at 105 clinical sites in the US and EU countries, incl. Czechia, France, Germany, Italy, Poland, Spain and the UK
  • The study met its 1EPs & 2EPs i.e., the therapy showed a significant improvement of 0.53hrs. in daily “Good On” time over-optimized IR CD/LD, with fewer daily doses when dosed a mean of 3 times per day with IPX203 vs 5 times per day
  • The results also showed that “good” on-time per dose increased by nearly 2hrs. with IPX203 & was found to be well tolerated. IPX203 is a novel, oral formulation of CD/LD extended-release capsules

Ref: Businesswire | Image: Amneal

Related News:- Amneal Receives Complete Response Letter on the NDA for IPX203 to Treat Parkinson’s Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Neha Madan

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions